Eleven Biotherapeutics (EBIO) Reports Q1 Loss of $0.25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Eleven Biotherapeutics Reports First Quarter 2017 Financial Results
May 4, 2017 7:08 AM EDT-- Continued Advancing Ongoing Phase 3 Registration Clinical Trial of Vicinium in Non-Muscle Invasive Bladder Cancer
-- Presented Preclinical Data at AACR Suggesting that Lead Compounds Induce Anti-Tumor Immune Response That Can Potentiate the Activity of Immuno-Oncology Agents --
-- Expanded Clinical Development Team to Support Ongoing and Planned Trials --
-- Management to Host Conference Call Today at 8:00 a.m. ET --
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical oncology company... More
